Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
RemeGen Co's Enterprise Value for the quarter that ended in Dec. 2025 was €4,489.3 Mil.
RemeGen Co's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €144.2 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RemeGen Co EV-to-EBIT Related Terms
RemeGen Co EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for RemeGen Co's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:REG vs VRTX, REGN, ALNY: EV-to-EBIT Comparison
For the Biotechnology subindustry, RemeGen Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
RemeGen Co EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, RemeGen Co's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where RemeGen Co's EV-to-EBIT falls into.
RemeGen Co's current Enterprise Value is €7,823.6 Mil.
RemeGen Co's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €144.2 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RemeGen Co (FRA:REG) has a EV-to-EBIT of 54.24 as of Jul. 22, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on RemeGen Co and its competitors. According to the industry distribution chart, RemeGen Co ranks #312 out of 372 companies in the Biotechnology industry, placing it in the top 83.9%.
Is RemeGen Co's EV-to-EBIT too high?
RemeGen Co's current EV-to-EBIT is 54.24. The Biotechnology industry median EV-to-EBIT is 13.48. RemeGen Co's value of 54.24 is 302.5% above this industry median. Based on the distribution chart, RemeGen Co ranks #312 out of 372 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, RemeGen Co has a GF Score™ of 41/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does RemeGen Co's EV-to-EBIT compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, RemeGen Co ranks #312 out of 372 companies for EV-to-EBIT. This places RemeGen Co in the lower half of its industry. The industry median EV-to-EBIT is 13.48. RemeGen Co's value of 54.24 is 302.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 13.48, based on 372 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. RemeGen Co's current EV-to-EBIT of 54.24 is 302.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on RemeGen Co and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 13.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. RemeGen Co's current EV-to-EBIT is 54.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RemeGen Co stock overvalued right now?
Based on GuruFocus' analysis, RemeGen Co (FRA:REG) is currently considered Possible Value Trap. The stock's GF Value™ is €21.66, compared to a current price of €9.30 — trading 57% below its estimated fair value. The current EV-to-EBIT is 54.24 and 302.5% above the Biotechnology industry median of 13.48. RemeGen Co's overall GF Score™ is 41/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For RemeGen Co (FRA:REG), the current EV-to-EBIT is 54.24 as of Jul. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is RemeGen Co (FRA:REG) Overvalued in 2026?
Based on GuruFocus' analysis, RemeGen Co stock appears to be undervalued.
The current stock price of €9.30 is trading 57% below its estimated GF Value™ of €21.66.
GuruFocus considers RemeGen Co to be Possible Value Trap.
Key valuation signals for FRA:REG:
EV-to-EBIT: 54.24
GF Value™: €21.66 vs. price of €9.30 (57% below fair value)
Industry Position: 302.5% above the Biotechnology median (#312 of 372)
No single metric tells the full story. See the FRA:REG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
RemeGen Co Ltd is a China-based company mainly engaged in the research, development and manufacture of biopharmaceuticals. The company offers Telitacicept (RC18) for use in the treatment of systemic lupus erythematosus an autoimmune disease and Disitamab Vedotin (RC48) for use in the treatment of various cancers. The company's products are mainly used to treat severe diseases such as autoimmune diseases, oncology, and ophthalmology. It has its operations in China and the USA and derives the majority of its revenue from China.
41GF Score
Get the complete analysis for FRA:REG
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:REG has been successfully added to your 
